S&P 500   3,678.43
DOW   29,490.89
QQQ   273.53
Being a Human Magnet Is Key to Your Company's Success. Here's What That Means.
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Near-Term Headwinds Send Nike To The Bargain Basement 
Sweden sends special diving vessel to area of pipeline leaks
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Russia's lower house of parliament endorses treaties for 4 regions of Ukraine to join Russia
Fraud, scam cases increasing on Zelle, Senate report finds
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
UK scraps tax cut for wealthy that sparked market turmoil
Supreme Court won't take up MyPillow head's defamation case
S&P 500   3,678.43
DOW   29,490.89
QQQ   273.53
Being a Human Magnet Is Key to Your Company's Success. Here's What That Means.
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Near-Term Headwinds Send Nike To The Bargain Basement 
Sweden sends special diving vessel to area of pipeline leaks
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Russia's lower house of parliament endorses treaties for 4 regions of Ukraine to join Russia
Fraud, scam cases increasing on Zelle, Senate report finds
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
UK scraps tax cut for wealthy that sparked market turmoil
Supreme Court won't take up MyPillow head's defamation case
S&P 500   3,678.43
DOW   29,490.89
QQQ   273.53
Being a Human Magnet Is Key to Your Company's Success. Here's What That Means.
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Near-Term Headwinds Send Nike To The Bargain Basement 
Sweden sends special diving vessel to area of pipeline leaks
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Russia's lower house of parliament endorses treaties for 4 regions of Ukraine to join Russia
Fraud, scam cases increasing on Zelle, Senate report finds
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
UK scraps tax cut for wealthy that sparked market turmoil
Supreme Court won't take up MyPillow head's defamation case
S&P 500   3,678.43
DOW   29,490.89
QQQ   273.53
Being a Human Magnet Is Key to Your Company's Success. Here's What That Means.
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Near-Term Headwinds Send Nike To The Bargain Basement 
Sweden sends special diving vessel to area of pipeline leaks
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Russia's lower house of parliament endorses treaties for 4 regions of Ukraine to join Russia
Fraud, scam cases increasing on Zelle, Senate report finds
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
UK scraps tax cut for wealthy that sparked market turmoil
Supreme Court won't take up MyPillow head's defamation case

Blueprint Medicines - BPMC Stock Forecast, Price & News

$66.42
+0.53 (+0.80%)
(As of 10/3/2022 12:00 AM ET)
Add
Compare
Today's Range
$64.97
$67.53
50-Day Range
$50.60
$77.70
52-Week Range
$43.46
$117.86
Volume
308,600 shs
Average Volume
763,834 shs
Market Capitalization
$3.96 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$92.06

Blueprint Medicines MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
38.6% Upside
$92.06 Price Target
Short Interest
Healthy
7.63% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.51mentions of Blueprint Medicines in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$3.30 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($9.35) to ($8.17) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

280th out of 1,093 stocks

Pharmaceutical Preparations Industry

122nd out of 548 stocks

BPMC stock logo

About Blueprint Medicines (NASDAQ:BPMC) Stock

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Receive BPMC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter.

BPMC Stock News Headlines

What 14 Analyst Ratings Have To Say About Blueprint Medicines
See More Headlines
Receive BPMC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter.

BPMC Company Calendar

Last Earnings
8/02/2022
Today
10/04/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BPMC
Fax
N/A
Employees
495
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$92.06
High Stock Price Forecast
$152.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+38.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
14 Analysts

Profitability

Net Income
$-644,090,000.00
Net Margins
-304.41%
Pretax Margin
-301.76%

Debt

Sales & Book Value

Annual Sales
$180.08 million
Book Value
$16.50 per share

Miscellaneous

Free Float
57,534,000
Market Cap
$3.96 billion
Optionable
Optionable
Beta
0.78

Key Executives

  • Mr. Jeffrey W. Albers J.D.Mr. Jeffrey W. Albers J.D. (Age 51)
    M.B.A., MBA, Exec. Chairman
    Comp: $1.38M
  • Ms. Kathryn Haviland (Age 46)
    Pres, CEO & Director
    Comp: $786.39k
  • Mr. Alexis A. Borisy A.M. (Age 50)
    Co-Founder & Director
    Comp: $46.64k
  • Mr. Michael Landsittel (Age 50)
    Chief Financial Officer
    Comp: $679.05k
  • Dr. Percy H. Carter M.B.A. (Age 51)
    Ph.D., Chief Scientific Officer
    Comp: $761.15k
  • Dr. Fouad Namouni M.D.Dr. Fouad Namouni M.D. (Age 53)
    Pres of R&D
    Comp: $986.52k
  • Ms. Christina RossiMs. Christina Rossi (Age 46)
    Chief Operating Officer
  • Dr. Christopher K. Murray (Age 59)
    Sr. VP of Technical Operations
  • Jenna Cohen
    Sr. Director & Head of Investor Relations
  • Ms. Tracey L. McCain Esq. (Age 54)
    Exec. VP, Chief Legal & Compliance Officer and Sec.













BPMC Stock - Frequently Asked Questions

Should I buy or sell Blueprint Medicines stock right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 2 sell ratings, 3 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BPMC shares.
View BPMC analyst ratings
or view top-rated stocks.

What is Blueprint Medicines' stock price forecast for 2022?

14 brokers have issued 1 year target prices for Blueprint Medicines' shares. Their BPMC share price forecasts range from $40.00 to $152.00. On average, they anticipate the company's stock price to reach $92.06 in the next twelve months. This suggests a possible upside of 38.6% from the stock's current price.
View analysts price targets for BPMC
or view top-rated stocks among Wall Street analysts.

How have BPMC shares performed in 2022?

Blueprint Medicines' stock was trading at $107.11 on January 1st, 2022. Since then, BPMC shares have decreased by 38.0% and is now trading at $66.42.
View the best growth stocks for 2022 here
.

When is Blueprint Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our BPMC earnings forecast
.

How were Blueprint Medicines' earnings last quarter?

Blueprint Medicines Co. (NASDAQ:BPMC) posted its quarterly earnings results on Tuesday, August, 2nd. The biotechnology company reported ($2.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.23) by $0.45. The biotechnology company had revenue of $36.55 million for the quarter, compared to analyst estimates of $37.61 million. Blueprint Medicines had a negative trailing twelve-month return on equity of 45.89% and a negative net margin of 304.41%. The firm's revenue was up 33.9% compared to the same quarter last year. During the same quarter last year, the company earned ($1.86) EPS.

What guidance has Blueprint Medicines issued on next quarter's earnings?

Blueprint Medicines issued an update on its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $180.00 million-$200.00 million, compared to the consensus revenue estimate of $194.85 million.

What is Kate Haviland's approval rating as Blueprint Medicines' CEO?

16 employees have rated Blueprint Medicines Chief Executive Officer Kate Haviland on Glassdoor.com. Kate Haviland has an approval rating of 100% among the company's employees. This puts Kate Haviland in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at Blueprint Medicines to a friend.

What other stocks do shareholders of Blueprint Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), QUALCOMM (QCOM), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR).

When did Blueprint Medicines IPO?

(BPMC) raised $115 million in an IPO on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Blueprint Medicines' stock symbol?

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

How do I buy shares of Blueprint Medicines?

Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Blueprint Medicines' stock price today?

One share of BPMC stock can currently be purchased for approximately $66.42.

How much money does Blueprint Medicines make?

Blueprint Medicines (NASDAQ:BPMC) has a market capitalization of $3.96 billion and generates $180.08 million in revenue each year. The biotechnology company earns $-644,090,000.00 in net income (profit) each year or ($11.87) on an earnings per share basis.

How many employees does Blueprint Medicines have?

The company employs 495 workers across the globe.

How can I contact Blueprint Medicines?

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.blueprintmedicines.com. The biotechnology company can be reached via phone at (617) 374-7580 or via email at ir@blueprintmedicines.com.

This page (NASDAQ:BPMC) was last updated on 10/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.